iScience (Sep 2024)

Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

  • Javier García-Pérez,
  • Alberto M. Borobia,
  • Mayte Pérez-Olmeda,
  • Antonio Portolés,
  • Luis Castaño,
  • Magdalena Campins-Artí,
  • María Jesús Bertrán,
  • Mercedes Bermejo,
  • José Ramón Arribas,
  • Andrea López,
  • Ana Ascaso-del-Rio,
  • Eunate Arana-Arri,
  • Inmaculada Fuentes Camps,
  • Anna Vilella,
  • Almudena Cascajero,
  • María Teresa García-Morales,
  • María Castillo de la Osa,
  • Carla Pérez Ingidua,
  • David Lora,
  • Paloma Jiménez-Santana,
  • Silvia Pino-Rosa,
  • Agustín Gómez de la Cámara,
  • Erick De La Torre-Tarazona,
  • Esther Calonge,
  • Raquel Cruces,
  • Cristóbal Belda-Iniesta,
  • José Alcamí,
  • Jesús Frías,
  • Antonio J. Carcas,
  • Francisco Díez-Fuertes,
  • Lucía Díaz García,
  • Elena Ramírez García,
  • Enrique Seco Meseguer,
  • Stefan Mark Stewart Balbàs,
  • Alicia Marín Candón,
  • Irene García García,
  • Mikel Urroz Elizalde,
  • Paula de la Rosa,
  • Marta Sanz García,
  • Cristina López Crespo,
  • Vega Mauleón Martínez,
  • Raquel de Madariaga Castell,
  • Laura Vitón Vara,
  • Rocío Prieto-Pérez,
  • Emilio Vargas-Castrillón,
  • Leonor Laredo,
  • Ouhao Zhu-Huang,
  • Teresa Iglesias,
  • Natale Imaz-Ayo,
  • Susana Meijide,
  • Aitor García de Vicuña,
  • Ana Santorcuato,
  • Iraide Exposito,
  • Sara de Benito,
  • Alazne Bustinza,
  • Mikel Gallego,
  • Dolores García-Vázquez,
  • Ana Belén de la Hoz,
  • Gustavo Pérez-Nanclares,
  • Josu Aurrekoetxea,
  • Ines Urrutia,
  • Rosa Martínez-Salazar,
  • Janire Orcajo,
  • Begoña Calvo,
  • June Corcuera,
  • Olaia Velasco,
  • Anibal Aguayo,
  • Xavier Martínez-Gómez,
  • Susana Otero-Romero,
  • Lluis Armadans,
  • Blanca Borras-Bermejo,
  • Oleguer Parés,
  • Sonia Uriona,
  • José Ángel Rodrigo Pendás,
  • Cesar Llorente,
  • José Santos,
  • Laia Pinós,
  • Lina Camacho,
  • Judith Riera,
  • Carla Sans,
  • Antonia Agustí,
  • Carmen Altadill,
  • Carla Aguilar Blancafort,
  • Gisela Gili Serrat,
  • Aitana Plaza,
  • Anna Feliu Prius,
  • Maria Margarita Torrens,
  • Esther Palacio,
  • Gloria Torres,
  • Julia Calonge,
  • Elena Ballarin Alins,
  • Eulàlia Pérez-Esquirol,
  • Lourdes Vendrell Bosch,
  • Marta Aldea,
  • Eugènia Mellado,
  • Ma Ángeles Marcos,
  • Marta Tortajada,
  • Lourdes E. Barón-Mira,
  • Laura Granés,
  • Sulayman Lazaar,
  • Sara Herranz,
  • Montserrat Malet,
  • Sebastiana Quesada,
  • Anna Llupià,
  • Victoria Olivé,
  • Antoni Trilla,
  • Begoña Gómez,
  • Elisenda González,
  • Sheila Romero,
  • Francisco Javier Gámez,
  • Cristina Casals,
  • Laura Burunat,
  • Juan José Castelló,
  • Patricia Fernández,
  • Josep Lluís Bedini,
  • Jordi Vila,
  • Juan Carlos Hurtado,
  • Isabel Jado,
  • Giovanni Fedele,
  • Concepción Perea,
  • Mónica González,
  • Isabel Grajera,
  • María Ángeles Murillo,
  • Pilar Balfagón,
  • Irene Díaz-Marín,
  • Gema González-Pardo

Journal volume & issue
Vol. 27, no. 9
p. 110728

Abstract

Read online

Summary: CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739).

Keywords